Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:bevacizumab
|
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
L01XC07
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alymsys
|
| gptkbp:indication |
gptkb:non-small_cell_lung_cancer
gptkb:cancer gptkb:fallopian_tube_cancer renal cell carcinoma metastatic colorectal cancer peritoneal cancer |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
mAbxience
|
| gptkbp:mechanismOfAction |
VEGF inhibitor
|
| gptkbp:product |
gptkb:Avastin
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:therapeuticArea |
oncology
|
| gptkbp:type |
biosimilar
|
| gptkbp:bfsParent |
gptkb:bevacizumab
|
| gptkbp:bfsLayer |
6
|